ORG 25935

Drug Profile

ORG 25935

Alternative Names: Glycine uptake inhibitor; ORG25935; SCH 900435

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Organon
  • Developer Merck & Co; Organon
  • Class Tetrahydronaphthalenes
  • Mechanism of Action Glycine transporter 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alcoholism; Panic disorder; Schizophrenia

Most Recent Events

  • 03 Mar 2010 Discontinued - Phase-II for Panic disorder in USA (PO)
  • 24 Feb 2010 Schering-Plough completes enrolment in a phase II trial for panic disorders in USA
  • 15 Jan 2008 Pharmacodynamics data from a preclinical study in rats and monkeys presented at the 20th Annual Congress of the European College of Neuropsychopharmacology (ECNP-2007)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top